Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cognition Therapeutics, Inc. (CGTX : NSDQ)

• Company Description    Cognition Therapeutics Inc.is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics Inc.is based in PURCHASE, N.Y. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $0.34 Daily Weekly Monthly 20 Day Moving Average: 1,307,915 shares Shares Outstanding: 61.99 (millions) Market Capitalization: $20.78 (millions) Beta: 0.88 52 Week High: $2.54 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.97% 4.48% 12 Week 2.48% -10.20% Year To Date -52.20% -54.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2500 WESTCHESTER AVENUE - PURCHASE,NY 10577 USA ph: 412-481-2210 fax: - info@cogrx.com http://www.cogrx.com

• General Corporate Information    Officers Lisa Ricciardi - Chief Executive Officer; President and Director Jack A. Khattar - Chairman John Doyle - Chief Financial Officer Aaron G. L. Fletcher - Director Brett P. Monia, - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 19243B102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 61.99 Most Recent Split Date: (:1) Beta: 0.88 Market Capitalization: $20.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.41 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.69 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 48.15% vs. Previous Quarter: 17.65% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -194.42 12/31/24 - -159.67 ROA 06/30/25 - - 03/31/25 - -115.14 12/31/24 - -103.70 Current Ratio 06/30/25 - - 03/31/25 - 2.09 12/31/24 - 2.65 Quick Ratio 06/30/25 - - 03/31/25 - 2.09 12/31/24 - 2.65 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.20 12/31/24 - 0.31 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©